Senior Scientist, Debiopharm International S.A.
David Cameron is a molecular microbiologist focused on developing new strategies to combat AMR. His early work was centred on defining genetic mechanisms of antibiotic resistance/tolerance and included research stints with Anton Peleg at Monash University in Melbourne, and Kim Lewis at Northeastern University in Boston. He arrived in Switzerland in 2018 where he worked closely with Yok-Ai Que to assess phage therapy for the treatment of staphylococcal infections in translational animal models. Currently, he is a senior scientist at Debiopharm International S.A. and functions as the lead microbiologist on each of the company’s anti-infective programs.